Drug intelligence / Profile preview

TNX-4000

Development stage: Preclinical
Lead developer: Tonix Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

TNX-4000 is a broad-spectrum, oral, small molecule cathepsin protease inhibitor with a host-directed mechanism. It was part of an antiviral technology portfolio acquired by Tonix Pharmaceuticals from Healion Bio in January 2023. The drug is being developed as a potential treatment for COVID-19 and other viral infections.

Targets

CTS (Cathepsin family)

Beyond the preview

Go deeper on TNX-4000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TNX-4000.

Explore the full profile